Literature DB >> 23588370

Osseous myxochondroid sarcoma: a detailed study of 5 cases of extraskeletal myxoid chondrosarcoma of the bone.

Elizabeth G Demicco1, Wei-Lien Wang, John E Madewell, Dali Huang, Marilyn M Bui, Julia A Bridge, Jeanne M Meis.   

Abstract

Extraskeletal myxoid chondrosarcoma (EMC) is a rare mesenchymal neoplasm with a characteristic translocation usually involving NR4A3 and EWSR1. EMC has rarely been reported in the bone and may be confused with conventional chondrosarcoma with myxoid features or various small round cell sarcomas. We present 5 cases of molecularly confirmed EMC arising primarily in the bone. Patients included 4 men and 1 woman, aged 38 to 77 years (median 54 y). Tumors arose in the ilium (2 cases), manubrium, rib, and humerus. Four tumors extensively infiltrated and destroyed preexisting bone with cortical breakthrough and associated soft tissue extension; 1 case demonstrated only focal cortical breakthrough. Microscopically, 2 cases had small round cell features; 1 of these was hypercellular, whereas the other was hypocellular with abundant myxochondroid matrix. Three cases were composed of eosinophilic spindled cells with variable fascicular to corded or wreath-like growth patterns. Fluorescence in situ hybridization was positive for both EWSR1 and NR4A3 translocation in 3 cases; rearrangement for EWSR1 or NR4A3, but not both, was seen in 2 tumors. After definitive therapy, 1 patient experienced multiple local recurrences at 36 months and died of disease at 61 months. Two patients developed lung metastases at 26 and 74 months and are alive with disease at 44 and 74 months, respectively. Two patients are disease free at 5 and 24 months. EMC of the bone is a diagnostic dilemma and requires molecular confirmation. We propose to classify tumors with the appropriate phenotype and molecularly confirmed NR4A3/EWSR1 rearrangements as myxochondroid sarcoma, either osseous or extraskeletal variants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23588370     DOI: 10.1097/PAS.0b013e3182796e46

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  5 in total

1.  INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma.

Authors:  Akihiko Yoshida; Naohiro Makise; Susumu Wakai; Akira Kawai; Nobuyoshi Hiraoka
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

2.  Primary intracranial extraskeletal myxoid chondrosarcoma: A case report and review of literature.

Authors:  Zi-You Zhu; Yu-Bo Wang; Han-Yi Li; Xin-Min Wu
Journal:  World J Clin Cases       Date:  2022-05-06       Impact factor: 1.534

3.  Primary intra-osseous myoepithelioma of phalanx mimicking an enchondroma.

Authors:  Aruna Nambirajan; Asit Ranjan Mridha; Mehar Chand Sharma; Ananya Panda; Aravindh Palaniswamy
Journal:  Skeletal Radiol       Date:  2016-08-14       Impact factor: 2.199

Review 4.  Mutation of KIT in cellular extraskeletal myxoid chondrosarcoma: a case report and literature review.

Authors:  Chen Wang; Zhi-Jie You; Xiao-Yan Chen; Jie Lin; Yi-Juan Wu
Journal:  Diagn Pathol       Date:  2022-04-29       Impact factor: 3.196

5.  Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study.

Authors:  Silvia Stacchiotti; Gian Paolo Dagrada; Roberta Sanfilippo; Tiziana Negri; Isabella Vittimberga; Stefano Ferrari; Federica Grosso; Gaetano Apice; Marco Tricomi; Chiara Colombo; Alessandro Gronchi; Angelo P Dei Tos; Silvana Pilotti; Paolo G Casali
Journal:  Clin Sarcoma Res       Date:  2013-12-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.